Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colm Keane

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell LymphomaColm Keane, Clare Gould, Kimberley Jones, et al.
British Journal of Haematology|June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceJoel C Wight, Mimi Yue, Colm Keane, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Oncotarget|November 10, 2018
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphomaQingyan Cui, Frank Vari, Alexandre S Cristino, et al.
The Lancet. Haematology|December 22, 2015
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyColm Keane, Frank Vari, Mark Hertzberg, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Journal of the National Cancer Institute|July 10, 2025
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survivalKimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, et al.
Blood Advances|June 22, 2021
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaKarthik Nath, Soi-Cheng Law, Muhammed B Sabdia, et al.
Blood Advances|June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialEliza A Hawkes, Jodie Palmer, Richard Khor, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell LymphomaColm Keane, Clare Gould, Kimberley Jones, et al.
British Journal of Haematology|June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceJoel C Wight, Mimi Yue, Colm Keane, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Oncotarget|November 10, 2018
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphomaQingyan Cui, Frank Vari, Alexandre S Cristino, et al.
The Lancet. Haematology|December 22, 2015
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyColm Keane, Frank Vari, Mark Hertzberg, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Journal of the National Cancer Institute|July 10, 2025
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survivalKimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, et al.
Blood Advances|June 22, 2021
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaKarthik Nath, Soi-Cheng Law, Muhammed B Sabdia, et al.
Blood Advances|June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialEliza A Hawkes, Jodie Palmer, Richard Khor, et al.
Pageof 7